Discovery of BPR1R024, an Orally Active and Selective CSF1R Inhibitor that Exhibits Antitumor and Immunomodulatory Activity in a Murine Colon Tumor Model.

MLA

Kun-Hung Lee, et al. “Discovery of BPR1R024, an Orally Active and Selective CSF1R Inhibitor That Exhibits Antitumor and Immunomodulatory Activity in a Murine Colon Tumor Model.” Journal of Medicinal Chemistry, vol. 64, no. 19, Oct. 2021, pp. 14477–97. EBSCOhost, https://doi.org/10.1021/acs.jmedchem.1c01006.

APA

Kun-Hung Lee, Wan-Ching Yen, Wen-Hsing Lin, Pei-Chen Wang, You-Liang Lai, Yu-Chieh Su, Chun-Yu Chang, Cai-Syuan Wu, Yu-Chen Huang, Chen-Ming Yang, Ling-Hui Chou, Teng-Kuang Yeh, Chiung-Tong Chen, Chuan Shih, & Hsing-Pang Hsieh. (2021). Discovery of BPR1R024, an Orally Active and Selective CSF1R Inhibitor that Exhibits Antitumor and Immunomodulatory Activity in a Murine Colon Tumor Model. Journal of Medicinal Chemistry, 64(19), 14477–14497. https://doi.org/10.1021/acs.jmedchem.1c01006

Chicago

Kun-Hung Lee, Wan-Ching Yen, Wen-Hsing Lin, Pei-Chen Wang, You-Liang Lai, Yu-Chieh Su, Chun-Yu Chang, et al. 2021. “Discovery of BPR1R024, an Orally Active and Selective CSF1R Inhibitor That Exhibits Antitumor and Immunomodulatory Activity in a Murine Colon Tumor Model.” Journal of Medicinal Chemistry 64 (19): 14477–97. doi:10.1021/acs.jmedchem.1c01006.